Wall Street brokerages expect Corium International Inc (NASDAQ:CORI) to announce sales of $7.07 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Corium International’s earnings. The highest sales estimate is $7.57 million and the lowest is $6.57 million. Corium International posted sales of $7.35 million during the same quarter last year, which suggests a negative year over year growth rate of 3.8%. The company is scheduled to issue its next quarterly earnings results on Thursday, May 10th.
On average, analysts expect that Corium International will report full-year sales of $7.07 million for the current financial year, with estimates ranging from $31.97 million to $33.93 million. For the next fiscal year, analysts forecast that the business will report sales of $39.28 million per share, with estimates ranging from $38.82 million to $39.74 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Corium International.
Corium International (NASDAQ:CORI) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.06. The business had revenue of $9.32 million during the quarter, compared to the consensus estimate of $7.48 million. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%.
In other news, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the firm’s stock in a transaction on Thursday, January 18th. The shares were bought at an average cost of $12.54 per share, with a total value of $6,395,400.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Perceptive Advisors Llc purchased 50,350 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were purchased at an average cost of $11.83 per share, for a total transaction of $595,640.50. The disclosure for this purchase can be found here. Company insiders own 30.80% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new stake in shares of Corium International during the 4th quarter worth about $123,000. New York State Common Retirement Fund acquired a new stake in shares of Corium International during the 2nd quarter worth about $158,000. California State Teachers Retirement System acquired a new stake in shares of Corium International during the 2nd quarter worth about $263,000. Teachers Advisors LLC acquired a new stake in shares of Corium International during the 2nd quarter worth about $272,000. Finally, California Public Employees Retirement System acquired a new stake in shares of Corium International during the 4th quarter worth about $310,000. 87.29% of the stock is currently owned by institutional investors.
Shares of Corium International (NASDAQ:CORI) traded down $0.90 on Monday, hitting $12.10. 2,553,009 shares of the stock were exchanged, compared to its average volume of 248,344. The company has a debt-to-equity ratio of 5.91, a current ratio of 1.40 and a quick ratio of 1.34. The stock has a market cap of $416.15, a P/E ratio of -7.34 and a beta of 1.59. Corium International has a 1-year low of $3.44 and a 1-year high of $13.93.
ILLEGAL ACTIVITY NOTICE: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3231629/corium-international-inc-cori-expected-to-announce-quarterly-sales-of-7-07-million.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.